1. Home
  2. EYPT vs SBGI Comparison

EYPT vs SBGI Comparison

Compare EYPT & SBGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EYPT
  • SBGI
  • Stock Information
  • Founded
  • EYPT 1987
  • SBGI 1986
  • Country
  • EYPT United States
  • SBGI United States
  • Employees
  • EYPT N/A
  • SBGI N/A
  • Industry
  • EYPT Biotechnology: Laboratory Analytical Instruments
  • SBGI Broadcasting
  • Sector
  • EYPT Industrials
  • SBGI Industrials
  • Exchange
  • EYPT Nasdaq
  • SBGI Nasdaq
  • Market Cap
  • EYPT 967.4M
  • SBGI 886.6M
  • IPO Year
  • EYPT 2005
  • SBGI 1995
  • Fundamental
  • Price
  • EYPT $14.50
  • SBGI $15.92
  • Analyst Decision
  • EYPT Strong Buy
  • SBGI Buy
  • Analyst Count
  • EYPT 5
  • SBGI 5
  • Target Price
  • EYPT $29.60
  • SBGI $21.00
  • AVG Volume (30 Days)
  • EYPT 1.4M
  • SBGI 595.5K
  • Earning Date
  • EYPT 11-05-2025
  • SBGI 11-05-2025
  • Dividend Yield
  • EYPT N/A
  • SBGI 6.34%
  • EPS Growth
  • EYPT N/A
  • SBGI N/A
  • EPS
  • EYPT N/A
  • SBGI N/A
  • Revenue
  • EYPT $42,339,000.00
  • SBGI $3,337,000,000.00
  • Revenue This Year
  • EYPT N/A
  • SBGI N/A
  • Revenue Next Year
  • EYPT N/A
  • SBGI $9.50
  • P/E Ratio
  • EYPT N/A
  • SBGI N/A
  • Revenue Growth
  • EYPT N/A
  • SBGI N/A
  • 52 Week Low
  • EYPT $3.91
  • SBGI $11.89
  • 52 Week High
  • EYPT $14.91
  • SBGI $18.46
  • Technical
  • Relative Strength Index (RSI)
  • EYPT 65.45
  • SBGI 55.53
  • Support Level
  • EYPT $13.43
  • SBGI $14.52
  • Resistance Level
  • EYPT $14.67
  • SBGI $17.88
  • Average True Range (ATR)
  • EYPT 0.91
  • SBGI 0.88
  • MACD
  • EYPT 0.32
  • SBGI -0.07
  • Stochastic Oscillator
  • EYPT 99.54
  • SBGI 40.96

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

About SBGI Sinclair Inc.

Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.

Share on Social Networks: